Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
The highly-anticipated fifth edition is here! Get the must-have resource for achieving compliance with medical device regulations.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
As marketing authorisation holders (MAHs) based in the UK begin to form plans to transfer their marketing authorizations (MAs) to holders established in the EU, Norway, Iceland and Liechtenstein, the European Medicines Agency (EMA) and European Commission on Wednesday released guidance to prepare industry for the UK’s withdrawal from the EU.
The question and answer document is the first in a series of guidances and follows a notice sent earlier this month to MAHs to begin preparations for Brexit. Outlined below are some of the sections and what companies can expect.
The Q&A says that such a sponsor will "need to transfer its designation to a holder established" in the European Economic Area (EEA), "or it will need to change its place of establishment to a Member State of the Union (or EEA) and submit the corresponding documentation through a change of name and/or address of the orphan designation holder procedure provided the legal entity remains the same."
The QPPV "must reside and carry out his/her tasks" in the EEA, the Q&A says. But the guidance notes that changes in the QPPV, including contact details (telephone and fax numbers, postal address and email address) may, for medicinal products for human use, be updated through the Article 57 database only (without the need for a variation)."
Another change that MAHs can make through the Article 57 database is the location of the PSMF to within the EEA. According to Commission Implementing Regulation (EU) No 520/2012, the PSMF must be located within the EEA.
And the qualified person of the manufacturing and importation authorization holder is responsible to certify that each batch of medicinal product intended to be placed on the EEA market was manufactured in accordance with EU good manufacturing practice requirements and the marketing authorization. For centrally authorized medicinal products, the guidance says the MAH will need to transfer its current UK-based site of batch release to a location established in the EEA and submit the corresponding variation.
Other questions deal with manufacturing sites of active substances and finished products located in the UK, and whether companies will still have access to financial and administrative assistance in accordance with Commission
Questions and Answers related to the United Kingdom's withdrawal from the European Union with regard to the medicinal products for human and veterinary use within the framework of the Centralised Procedure
Tags: Brexit, QPPV, PSMF, batch release, orphan products, MAHs and Brexit